Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Drug Interactions in Cancer Therapy
share announcement

Drug Interactions in Cancer Therapy

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 3025

Special Issue Editors

Dr. Gabriella Marfe

E-Mail Website
Guest Editor
Department of Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche, University of Campania "Luigi Vanvitelli," via Vivaldi 43, 81100 Caserta, Italy
Interests: cancer therapy; drug resistance; radiology; biochemistry
Dr. Abhishek Shankar

E-Mail Website
Guest Editor
Department of Radiation Oncology, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Delhi, India
Interests: radiation oncology; cancer therapy

Special Issue Information

Dear Colleagues,

The Global burden of cancer (GLOBOCAN) 2020 reported a 19.3 million new cases of cancer and almost 10.0 million died due to cancer. In addition, GLOBOCAN predicts that the number of cancer cases will increase to 28.4 million in 2040. In the future, female breast cancer will be the most common cancer (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), and stomach (5.6%). As far as cancer-related mortality is concerned, lung cancer is the leading cause, responsible for 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%). The use of cytotoxic agents in chemotherapy is to cure cancer and, very often, they are administered as multiple drug regimens along with other medicines to achieve maximum therapeutic benefit and counter the adverse effects of chemotherapy or to treat other co-illnesses. It has been estimated that approximately 4% of cancer patients die due to adverse effects provoked by drug interactions

This Special Issue will be aimed at studies on:

  • The most common interacting drugs used in cancer patients
  • Identifying predictors of potential drug interaction to decrese avoidable drug-related problems
  • Studying their implications on the pharmacokinetics of the drugs
  • Describing pathway-based predictive biomarkers across multiple tumor types for the response to different compounds
  • Analyzing potential drug interactions early in the drug-development process, via in vitro model systems.

Dr. Gabriella Marfe
Dr. Abhishek Shankar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

14 pages, 2314 KiB  
Article
Unexpected Adverse Events of Immune Checkpoint Inhibitors
by Walid Shalata, Alexander Yakobson, Aharon Y. Cohen, Iris Goldstein, Omar Abu Saleh, Yulia Dudnik and Keren Rouvinov
Life 2023, 13(8), 1657; https://doi.org/10.3390/life13081657 - 29 Jul 2023
Cited by 5 | Viewed by 1431
Abstract
The introduction of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment standards and significantly enhanced patient prognoses. However, the utilization of these groundbreaking therapies has led to the observation and reporting of various types of adverse events, commonly known as immune-related adverse events [...] Read more.
The introduction of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment standards and significantly enhanced patient prognoses. However, the utilization of these groundbreaking therapies has led to the observation and reporting of various types of adverse events, commonly known as immune-related adverse events (irAEs). In the following article, we present four patients who encountered uncommon toxicities induced by ICIs. The first patient was a 59-year-old female diagnosed with stage 4 lung adenocarcinoma. She received immunotherapy (pembrolizumab) together with chemotherapy and subsequently developed autonomic neuropathy (AN). The next two patients also received chemo-immunotherapy (pembrolizumab) and were both 63-year-old males with stage 4 lung adenocarcinoma. One of the two experienced palmoplantar keratoderma, while the other presented with Reiter’s syndrome (urethritis, conjunctivitis and arthritis). The 4th patient, an 80-year-old male with stage 4 squamous cell carcinoma of the lung, received chemo-immunotherapy (pembrolizumab) and developed myasthenia gravis. Full article
(This article belongs to the Special Issue Drug Interactions in Cancer Therapy)
►▼ Show Figures

Figure 1

Other

Jump to: Research

8 pages, 26367 KiB  
Case Report
Radiotherapy-Induced Atrial Myxoma: A Case Report and Literature Review
by Walid Shalata, Ismaell Massalha, Shlomo Yaron Ishay, Elena Chernomordikova, Ashraf Abu Jama, Keren Rouvinov, Yulia Dudnik and Alexander Yakobson
Life 2023, 13(7), 1585; https://doi.org/10.3390/life13071585 - 19 Jul 2023
Cited by 2 | Viewed by 1105
Abstract
In this particular case study, we present a 66-year-old male who was diagnosed with an atrial myxoma eight years after receiving treatment for non-small cell lung cancer. The patient underwent chemo-radiotherapy (mediastinal area) in 2012 to address stage III-A adenocarcinoma of the lung. [...] Read more.
In this particular case study, we present a 66-year-old male who was diagnosed with an atrial myxoma eight years after receiving treatment for non-small cell lung cancer. The patient underwent chemo-radiotherapy (mediastinal area) in 2012 to address stage III-A adenocarcinoma of the lung. During follow-up imaging in 2020, a left atrial mass displaying characteristic features of a cardiac myxoma was detected. Upon reviewing a computed tomographic (CT) scan from 2017 within the previously irradiated mediastinal region, the cardiac mass was retrospectively identified. The surgical excision of the cardiac mass was performed, and a subsequent pathological examination confirmed the diagnosis of myxoma. To the best of our knowledge, this is the first reported case of a left atrial myxoma in a patient previously treated for adenocarcinoma of the lung and the first instance of an atrial myxoma occurring in a site that had undergone prior radiation therapy. Full article
(This article belongs to the Special Issue Drug Interactions in Cancer Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop